Immunogenicity and Blocking Efficacy of Norovirus GII.4 Recombinant P Protein Vaccine

Noroviruses (NoVs) are the main cause of acute gastroenteritis in all ages worldwide. The aim of this study was to produce the recombinant P protein of norovirus and to demonstrate its blocking effect. In this study, the engineered strains were induced to express the P protein of NoVs GII.4, which was identified using SDS-PAGE and ELISA as having the capacity to bind to histo-blood group antigens (HBGAs). Rabbits were immunized to obtain neutralizing antibodies. ELISA and ISC-RT-qPCR were used to determine the blocking efficacy of the neutralizing antibody to human norovirus (HuNoV) and murine norovirus (MNV). The recombinant P protein (35 KD) was obtained, and the neutralizing antibody was successfully prepared. The neutralizing antibody could block the binding of the P protein and HuNoV to HBGAs. Neutralizing antibodies can also block MNV invasion into host cells RAW264.7. The recombinant P protein expressed in E. coli can induce antibodies to block HuNoV and MNV. The recombinant P protein of NoVs GII.4 has the value of vaccine development.

Automated summary

This study aimed to produce the recombinant P protein of norovirus and examine its blocking effect. The engineered strains expressed the P protein of NoVs GII.4, which showed binding capacity to histo-blood group antigens (HBGAs) through SDS-PAGE and ELISA. Rabbits were immunized to obtain neutralizing antibodies, which were found to block the binding of the P protein and human norovirus (HuNoV) to HBGAs. The recombinant P protein can induce antibodies to block HuNoV and murine norovirus (MNV) invasion.